Insider Selling: Laboratory Corp. of America Holdings (NYSE:LH) SVP Sells $411,474.00 in Stock

Laboratory Corp. of America Holdings (NYSE:LH) SVP Der Vaart Sandra D. Van sold 2,328 shares of Laboratory Corp. of America stock in a transaction on Monday, July 8th. The shares were sold at an average price of $176.75, for a total transaction of $411,474.00. Following the completion of the transaction, the senior vice president now directly owns 2,328 shares of the company’s stock, valued at approximately $411,474. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

LH stock opened at $175.45 on Friday. The stock has a market capitalization of $17.19 billion, a PE ratio of 15.92, a P/E/G ratio of 1.80 and a beta of 1.04. The stock’s 50-day moving average is $169.30. The company has a quick ratio of 1.05, a current ratio of 1.14 and a debt-to-equity ratio of 0.77. Laboratory Corp. of America Holdings has a 52 week low of $119.38 and a 52 week high of $188.65.

Laboratory Corp. of America (NYSE:LH) last released its earnings results on Tuesday, April 30th. The medical research company reported $2.62 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.09. The business had revenue of $2.79 billion during the quarter, compared to analysts’ expectations of $2.82 billion. Laboratory Corp. of America had a net margin of 8.59% and a return on equity of 16.59%. The company’s quarterly revenue was down 2.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.78 earnings per share. On average, equities research analysts expect that Laboratory Corp. of America Holdings will post 11.27 earnings per share for the current year.

LH has been the subject of a number of recent analyst reports. Mizuho set a $31.00 price objective on shares of Evolus and gave the company a “buy” rating in a report on Monday, May 20th. Zacks Investment Research cut shares of G1 Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, May 16th. Canaccord Genuity reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Chembio Diagnostics in a report on Thursday, May 2nd. Jefferies Financial Group reaffirmed a “sell” rating on shares of Hi-Crush Partners in a report on Tuesday, April 2nd. Finally, Barclays reaffirmed a “buy” rating and issued a $304.00 price objective on shares of Adobe in a report on Monday, March 18th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $181.33.

Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its position in Laboratory Corp. of America by 2.6% during the first quarter. BlackRock Inc. now owns 10,029,286 shares of the medical research company’s stock worth $1,534,283,000 after acquiring an additional 257,173 shares during the last quarter. Nordea Investment Management AB boosted its position in Laboratory Corp. of America by 7.3% during the fourth quarter. Nordea Investment Management AB now owns 2,120,509 shares of the medical research company’s stock worth $267,945,000 after acquiring an additional 143,426 shares during the last quarter. FMR LLC boosted its position in Laboratory Corp. of America by 81.4% during the first quarter. FMR LLC now owns 1,596,659 shares of the medical research company’s stock worth $244,257,000 after acquiring an additional 716,703 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Laboratory Corp. of America by 2.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,460,214 shares of the medical research company’s stock worth $184,501,000 after acquiring an additional 34,797 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Laboratory Corp. of America by 8.6% during the fourth quarter. Geode Capital Management LLC now owns 1,412,093 shares of the medical research company’s stock worth $178,140,000 after acquiring an additional 111,859 shares during the last quarter. 91.45% of the stock is owned by institutional investors and hedge funds.

Laboratory Corp. of America Company Profile

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.

Recommended Story: Municipal Bonds

Insider Buying and Selling by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.